The contagious optimism at BIO-Europe 2026
At hollandbio, we’re big fans of BIO-Europe. For this year’s edition, Wieteke and Dora hopped on the train to Cologne to meet biotech entrepreneurs and others across the ecosystem. A great opportunity to hear firsthand how fundraising is going, where new business is coming from and, above all, how entrepreneurs see the road ahead. And once again, we came back infected with something we’re particularly susceptible to: the optimism of biotech entrepreneurs.
If there is one thing that stands out when talking to biotech founders and teams, it is their extraordinary combination of brains, talent, drive and optimism. They know better than anyone that biotech is difficult. Development takes years, capital requirements are huge, clinical trials are expensive, and failure is always a possibility. And still, they keep going. Not because they underestimate the challenge, but because they see the possibility. A new treatment. A better technology. A patient who currently has no options. And if there is a chance to make a difference, they are willing to pursue it. That optimism is not naïve. It is the fuel that turns scientific possibility into progress. And honestly, it is contagious. Every time we hear biotech entrepreneurs talk about what they are building and what could become possible, we leave even more determined to improve the conditions for them to succeed.
Great ideas need great ecosystems
A theme that ran through almost every conversation: where, and with whom to build? Biotech innovations do not develop on scientific excellence alone. Turning an idea into a product requires talented teams, investors with deep pockets and deep sector expertise, clinical development partners, manufacturing capabilities, regulatory know-how, customers and international networks. With the enormous costs and long timelines involved, access to capital and financial expertise is not a nice-to-have, but a prerequisite.
The global playing field is changing fast
What also stood out, is that Asia is not waiting for Europe. China and India have built sophisticated biotech ecosystems and are actively competing for talent, companies, capital and innovation. The old reflexes of questioning whether they can compete or deliver on quality are detached from reality. In the end the ambitions are the same: stronger economies, healthier citizens and leadership in the technologies that will shape the future.
Innovation climate that matches ambition
Although the global playing field is rapidly changing, there is no need to be pessimistic. Europe, and the Netherlands in particular, still has an extraordinary hand to play. We have fantastic science, talented entrepreneurs, strong networks and collaborations, excellent healthcare and a long history of biotech innovation.
But having a good hand does not guarantee a seat at tomorrow’s table. The Netherlands will never win by being the biggest market for biotech launches, nor by having the deepest pools of investment capital. We therefore need to compete on what does set us apart: speed, agility, ingenuity and an ecosystem that makes it easier for ambitious biotech entrepreneurs to build, finance, test, scale and grow. The entrepreneurs are eager and ready, their ideas ambitious and their optimism contagious. Let’s make sure the environment surrounding them matches that ambition. Missed us at BIO-Europe, or have something to share? Let hollandbio’s Dora know.
